SEC 13F Intelligence

Managers / Q1 2019 · view latest →

Boxer Capital, LLC

CIK 0001465837 · 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO, CA, 92130 · (858) 400-3112

Reported Value
$865M
Q1 2019
Positions
23
Filings on Record
27
2019–present window
Filed
May 15, 2019
original filing

Summary

Boxer Capital, LLC reported $865M in U.S.-listed holdings across 23 positions for Q1 2019.

Its largest position, MRTXEUR, represents 14.5% of the portfolio.

Compared with Q4 2018, the fund opened 3 new positions and exited 4.

Portfolio Metrics

Turnover
+31.3%
vs prior filed quarter
Top-10 Concentration
+75.1%
share of reported value
Largest Position
+14.5%
Mirati Therapeutics
New / Exited
3 / 4
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $809MQ4 ’18Q1 ’19: $865MQ2 ’19: $1.2BQ3 ’19: $1.4BQ3 ’19Q4 ’19: $1.8BQ1 ’20: $1.5BQ2 ’20: $2.3BQ2 ’20Q3 ’20: $2.9BQ4 ’20: $3.1BQ1 ’21: $2.9BQ1 ’21Q2 ’21: $2.8BQ3 ’21: $2.9BQ4 ’21: $2.6BQ4 ’21Q1 ’22: $1.9BQ2 ’22: $1.6BQ3 ’22: $1.8BQ3 ’22Q4 ’22: $1.9BQ2 ’23: $2MQ4 ’23: $2.0BQ4 ’23Q1 ’24: $2.0BQ2 ’24: $1.9BQ3 ’24: $2.0BQ3 ’24Q4 ’24: $0filingsflow.com

Portfolio Composition

By security type
Common Stock: 59.6%Other: 26.7%ADR: 13.7%
  • Common Stock · 59.6% · $515M
  • Other · 26.7% · $231M
  • ADR · 13.7% · $119M

Quarter-over-Quarter Changes full breakdown →

vs Q4 2018 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
BIIBBIOGEN INCNEW+200.0K200.0K+$47M$47M
GOSSGOSSAMER BIO INCNEW+1.88M1.88M+$41M$41M
ALLKGUSDALLAKOS INCNEW+799.0K799.0K+$32M$32M
IMMUIMMUNOMEDICS INCADDED+2.95M4.10M+$62M$79M
MDCOUSDMEDICINES COADDED+368.0K600.0K+$12M$17M
ICPTUSDINTERCEPT PHARMACEUTICALS INSOLD OUT−600.0K0−$60M$0
AMARIN CORP PLCSOLD OUT−1.50M0−$20M$0
ESPERION THERAPEUTICS INC NESOLD OUT−100.0K0−$5M$0

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2019

23 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1MRTXEURMIRATI THERAPEUTICS INChistory →COM14.54%$126M1.72M
2ONCBEIGENE LTDhistory →SPONSORED ADR13.74%$119M900.0K
3IMMUIMMUNOMEDICS INChistory →COM9.11%$79M4.10M
4ODONATE THERAPEUTICS INCCOM7.62%$66M2.98M
5UNIQURE NVSHS6.55%$57M950.0K
6BIIBBIOGEN INChistory →COM5.47%$47M200.0K
7GOSSGOSSAMER BIO INChistory →COM4.70%$41M1.88M
8ESPRESPERION THERAPEUTICS INC NEhistory →COM4.53%$39M975.0K
9WAVE LIFE SCIENCES LTDSHS4.49%$39M1.00M
10PTCTPTC THERAPEUTICS INChistory →COM4.35%$38M1.00M
11DBV TECHNOLOGIES S ASPONSORED ADR3.74%$32M4.20M
12ALLKGUSDALLAKOS INChistory →COM3.74%$32M799.0K
13SOLID BIOSCIENCES INCCOM3.70%$32M3.47M
14RCKTROCKET PHARMACEUTICALS INChistory →COM2.97%$26M1.47M
15MDCOUSDMEDICINES COhistory →COM1.94%$17M600.0K
16CYMABAY THERAPEUTICS INCCOM1.92%$17M1.25M
17KURAKURA ONCOLOGY INChistory →COM1.62%$14M844.8K
18GBTUSDGLOBAL BLOOD THERAPEUTICS INhistory →COM1.53%$13M250.0K
19MTNBEURMATINAS BIOPHARMA HLDGS INChistory →COM1.28%$11M10.19M
20MEI PHARMA INCCOM NEW1.03%$9M2.91M
214XC1KALVISTA PHARMACEUTICALS INCCOM0.66%$6M200.0K
22KINIKSA PHARMACEUTICALS LTDCOM CL A0.61%$5M290.6K
23TKAIEURNOVUS THERAPEUTICS INCCOM0.15%$1M324.4K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q4 2024$01Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$2.0B68Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$1.9B61Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$2.0B59May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$2.0B52Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023Under review73Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$2M79Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023Under review75May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$1.9B71Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$1.8B73Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$1.6B76Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$1.9B74May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$2.6B71Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$2.9B88Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$2.8B95Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$2.9B85May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$3.1B78Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$2.9B75Nov 17, 2020RESTATEMENTchanges · EDGAR ↗
Q2 2020$2.3B65Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$1.5B62May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$1.8B51Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$1.4B49Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019REVEALED$1.2B37Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$865M23May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$809M24Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.